2-氨基嘧啶-4-羧酸 | 2164-65-0

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 其他氨基酸衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-氨基嘧啶-4-羧酸
• 中文别名: 2-氨基-4-嘧啶甲酸
• 英文名称: 2-aminopyrimidine-4-carboxylic acid
• CAS: 2164-65-0
• 化学式: C₅H₅N₃O₂
• 分子量: 139.114
• InChiKey: GKFPFLBDQJVJIH-UHFFFAOYSA-N

物化性质

• 熔点：
  285 °C
• 沸点：
  474.6±37.0 °C(Predicted)
• 密度：
  1.533±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  89.1
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 安全说明：
  S24/25,S36/37
• 危险类别码：
  R20/21/22
• 海关编码：
  2933599090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Aminopyrimidine-4-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Aminopyrimidine-4-carboxylic acid
CAS number: 2164-65-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H5N3O2
Molecular weight: 139.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氨基嘧啶-4-羧酸 在 盐酸 作用下， 以 1,4-二氧六环 、 乙腈 为溶剂， 反应 4.0h， 生成 methyl 2-(3-bromo-1-(4-methoxybenzyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrimidine-7-carboxylate
  参考文献：
  名称：

  WO2024083773A1

  摘要：

  公开号：
• 作为产物：
  描述：

  2-嘧啶胺 在 potassium permanganate 作用下， 生成 2-氨基嘧啶-4-羧酸
  参考文献：
  名称：

  Matsukawa; Sirakawa, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1952, vol. 72, p. 913

  摘要：

  DOI：

文献信息

• HETEROCYCLIC ANTIVIRAL COMPOUNDS
  申请人：Broka Chris Allen

  公开号：US20110070190A1

  公开（公告）日：2011-03-24

  The invention discloses 1-N-substituted-6-(hetero)aryl-1H-thieno[3,2-d]pyrimidin-4-one derivatives of formula wherein R 1 , R 2 , R 3 and R 4 are as defined herein that inhibit Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.

  该发明揭示了公式的1-N-取代-6-(杂)芳基-1H-噻吩[3,2-d]嘧啶-4-酮衍生物 其中R 1 ，R 2 ，R 3 和R 4 如本文所定义，抑制丙型肝炎病毒NS5b聚合酶抑制剂。还公开了治疗HCV感染和抑制HCV复制的组合物和方法。
• ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS
  申请人：Yamagishi Tatsuya

  公开号：US20140336377A1

  公开（公告）日：2014-11-13

  The present invention relates to arylamide derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

  本发明涉及一种芳基酰胺衍生物，其具有阻断电压门控钠通道（如TTX-S通道）的活性，并且在涉及电压门控钠通道的疾病和疾病的治疗或预防中有用。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在涉及电压门控钠通道的这种疾病的预防或治疗中的使用。
• Arylamide derivatives as TTX-S blockers
  申请人：Yamagishi Tatsuya

  公开号：US09302991B2

  公开（公告）日：2016-04-05

  The present invention relates to arylamide derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

  本发明涉及芳基酰胺衍生物，其具有阻断电压门控钠通道（TTX-S通道）的活性，并且在治疗或预防涉及电压门控钠通道的疾病和疾病方面有用。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗涉及电压门控钠通道的疾病方面使用这些化合物和组合物。
• NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES
  申请人：Borjesson Lena

  公开号：US20090156575A1

  公开（公告）日：2009-06-18

  The invention provides compounds of general formula wherein A, B, p, w, x, y, and z are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了一般式为的化合物，其中A、B、p、w、x、y和z的定义如规范中所述，以及其制备方法、包含它们的药物组合物和它们在治疗中的应用。
• Discovery of 2-(Anilino)pyrimidine-4-carboxamides as Highly Potent, Selective, and Orally Active Glycogen Synthase Kinase-3 (GSK-3) Inhibitors
  作者：Richard A. Hartz、Vijay T. Ahuja、Guanglin Luo、Ling Chen、Prasanna Sivaprakasam、Hong Xiao、Carol M. Krause、Wendy J. Clarke、Songmei Xu、John S. Tokarski、Kevin Kish、Hal Lewis、Nicolas Szapiel、Ramu Ravirala、Sayali Mutalik、Deepa Nakmode、Devang Shah、Catherine R. Burton、John E. Macor、Gene M. Dubowchik

  DOI：10.1021/acs.jmedchem.3c00364

  日期：2023.6.8

  pyrimidine-based hinge-binding heterocycle was synthesized and evaluated, leading to the identification of highly potent GSK-3 inhibitors with excellent kinase selectivity. Further evaluation of 34 and 40 in vivo demonstrated that these compounds are orally bioavailable, brain-penetrant GSK-3 inhibitors that lowered levels of phosphorylated tau in a triple-transgenic mouse Alzheimer’s disease model.

  糖原合成酶激酶 3 (GSK-3) 是一种丝氨酸/苏氨酸激酶，是多种细胞功能的重要调节剂。它与阿尔茨海默病以及各种其他疾病有关，包括情绪障碍、2 型糖尿病和癌症。有大量证据表明，中枢神经系统中的 GSK-3β 在与阿尔茨海默病相关的神经原纤维缠结中发现的异常、过度磷酸化、微管相关 tau 蛋白的产生中发挥着作用。合成并评估了一系列含有基于嘧啶的铰链结合杂环的类似物，从而鉴定出具有优异激酶选择性的高效 GSK-3 抑制剂。进一步评估34和40体内实验证明，这些化合物是口服生物可利用的、脑渗透性 GSK-3 抑制剂，可降低三重转基因小鼠阿尔茨海默病模型中磷酸化 tau 的水平。